<< Вернуться к списку статей журнала

Том 7 №1 2005 год - Нефрология и диализ

Мофетила микофенолат в лечении гломерулярных болезней: экспериментальные и клинические данные (Обзор литературы)

Приходина Л.С. Длин В.В.

Аннотация: Частота идиопатического нефротического синдрома (НС) в детской популяции в Европе составляет 2:100 000 [27, 84, 85]. 80-90% детей с НС чувствительны к стероидной терапии, однако у 76-93% из них в последующем отмечается рецидивирование НС или развивается стероидная зависимость [44, 59, 89]. Cтероид-резистентный НС (СРНС) наблюдается у 7-18% детей, при этом в последние годы отмечается тенденция к увеличению его частоты

Для цитирования: Приходина Л.С., Длин В.В. Мофетила микофенолат в лечении гломерулярных болезней: экспериментальные и клинические данные (Обзор литературы). Нефрология и диализ. 2005. 7(1):25-31. doi:

Весь текст

Ключевые слова: мофетила микофенолат, нефротический синдром, дети

Список литературы:

1. Баранова Ф.С., Мойсюк Я.Г. Иммунология в клинической аллотрансплантации органов. Иммунодепрессия. В кн.: Трансплантология. Руководство под ред. В.И. Шумакова. М.: Медицина, 1995; 62-71.
2. Вознесенская Т.С., Сергеева Т.В. Мофетила микофенолат в терапии нефропатического синдрома у детей. Нефрология и диализ 2003; 5; 1: 45-47.
3. Игнатова М.С., Курбанова Э.Г. Иммуносупрессивная терапия нефротического синдрома у детей. М.: 2000: 101.
4. Тареева И.Е. Нефрология. М.: Медицина, 2000: 414.
5. Al-Lehbi A.M., Al-Mutairi M.A., Al-Meshari K.A. et al. Mycophenolate mofetil in steroid resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 1999: 94F.
6. Allison A.C., Eugui E.M. Mycophenolate Mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
7. Allison A.C., Eugui E.M., Sollinge H.W. Mycophenolate Mofetil (RS-61443): Mechanism of action and effects in transplantation. Transplant Rev 1993; 7: 129-139.
8. Allison A.C., Kowalski W.J., Muller C.J., Walters R.V., Eugui E.M. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993; 25: 67-70.
9. Aviles D.H., Irwin K.C., Dublin L.S., Vehaskari V.M. Aggressive treatment of severe idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol 1999; 13: 298-300.
10. Badid C., Desmouliere A., Laville M. MMF: implication for the treatment of glomerular diseases. Nephrol Dial Transplant 2001; 16: 1752-1756.
11. Badid C., Vincent M., McGregor B. et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 51-61.
12. Baer P.C., Cauer S., Hauser I.A., Scherberich J.E., Geiger H. Effects of mycophenolic acid on human renal proximal and distal tubular cells in vitro. Nephrol Dial Transplant 2000; 15: 184-190.
13. Barletta G.M., Smoyer W.E., Bunchman T.E., Flynn J.T., Kershaw D.B. Use of mycophenolate mofetil in steroid-dependent and - resistant nephrotic syndrome. Pediatr Nephrol 2003; 18: 833-837.
14. Bartosh S.M. The use of mycophenolate mofetil in children with nephrotic syndrome. J Am Soc Nephrol 1999; 10: 95A.
15. Blaneta R.A., Leskel K., Wittig B. et al. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transpl Immunol 1998; 6: 251-259.
16. Briggs W.A., Choi M.J., Gimenez L.F., Scheel P.J. Treatment of primary glomerulopathies (1GN) with mycophenolate mofetil (abstract). Abstracts of the ASN 31st Annual Meeting, October 1998, Philadelphia, Pa., Abstract 437.
17. Briggs W.A., Choi M.J., Scheel P.J. Follow-up on mycophenolate mofetil treatment of glomerular diseases. Am J Kidney Dis 1998; 31: 898-899.
18. Burgess E. Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int (Suppl.) 1999; 70: S26-S32.
19. Cameron J.S., Turner D.R., Ogg C.S., Chantler C., Williams D.G. The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 1978; 10: 213-218.
20. Caropreso M.R., Ferretti A.V., Margieri G. et al. Mycophenolate mofetil in the treatment of children with steroid-dependent nephritic syndrome. Nephrol Dial Transplant 2003; 18 (Suppl. 4): 65.
21. Cattran D.C., Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998; 32: 72-79.
22. Chan T.M., Li F.K., Tang C.S., Wong R.W., Fang G.X., Ji Y.L., Lau C.S., Wong A.K., Tong M.K., Chan K.W., Lai K.N. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 19: 1156-1162.
23. Chandra M., Susin M. Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil. Pediatr Nephrol 2000; 14: 224-226.
24. Chen X.M., Cai G., Zhang Y., Qiu Q., Cheng Q. Control study of effects of mycophenolate mofetil on IgA nephropathy. J Am Soc Nephrol 2000; 11: 57A.
25. Chen X.M., Сhen P., Cai G. et al. A randomized control trial of mycophenolate mofetil treatment in severe IgA nephropathy. Zhonghua Yixue Za Zhi 2002; 25; 82 (12): 796-801.
26. Choi M.J., Eustace J.A., Gimenex L.F., Atta M.G., Scheel P.J., Sothinathan R., Briggs W.A. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61: 1098-1114.
27. Clark A.G., Barratt T.M. Steroid-responsive nephrotic syndrome. In: Barratt T.M., Avner E.D., Harmon WE. (eds). Pediatr Nephrology, 4th edn. Lippincott, Williams and Wilkins, Baltimore, 1999: 731-747.
28. Cohn R.G., Mircovich A., Dunlap B. et al. Mycophenolic acid increases apoptosis in lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999; 68: 411-418.
29. Collaborative Study Group of Sandimmune in Nephrotic Syndrome. Safety and tolerability of Cyclosporin A (Sandimmune) in idiopathic nephrotic syndrome. Clin Nephrol 1991; 35: S48-S60.
30. Corna D., Morigi M., Facchinetti T. et al. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51 (5): 1583-1589.
31. Day C.J., Cockwell P., Lipkin G.W. et al. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Neph Dial Transpl 2002; 17 (11): 2011-2013.
32. De Mattos A.M., Olyali A.J., Bennett W.M. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am О Kidney Dis 2000; 35: 333-346.
33. Dooley M.A., Cosio F.G., Nachman P.H. et al. Mycophenolate mofetil therapy in lupus-nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833-839.
34. Dubus I., Vendrely B., Christophe I. et al. Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int 2002; 62 (3): 857-867.
35. Durkan A.M., Hodson E.M., Willis N.S., Craig J.C. Immunosupressive agents in childhood nephrotic syndrome: A meta-analysis of randomized controlled trials. Kidney Int 2001; 59: 1919-1927.35a. ESPN handbook, 2002: p371.
36. Eugui E.M., Amquist S.J., Muller C.D., Allison A.C. Lymphocytoselective citostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33: 161-173.
37. Eugui E.M., Mircovich A., Allison A.C. Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol 1991; 33: 175.
38. European Mycophenolate mofetil cooperative study group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
39. Filler G., Hansen M., LeBlanc C. et al. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 2003; 18 (5): 445-449.
40. Fu Y.F., Liu G.L. Mycophenolate Mofetil Therapy for children with lupus nephritis refractory to both intravenous cyclophosphamide and cyclosporine. Clin Nephrol 2001; 55: 318-321.
41. Fujihara C.K., Avancini Costa Malheiros D.M., de Lourdes Noronha I. et al. Mycophenolate mofetil reduces renal injury in the chronic nitric oxide synthase inhibition model. Hypertension 2001; 37 (1): 170-175.
42. Fujihara C.K., Malheiros D., Zatz R., Norohna I.L. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int 1998; 54: 1510-1519.
43. Fujihara C.K., Norohna I.L., Malheiros D. et al. Combined mycophenolate mofetil and losartran therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11: 283-290.
44. Gellerman J., Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil. Pediatr Nephrol 2004; 19: 101-104.
45. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993; 11: 117-119.
46. Goldsmith M.P. Researches follow varied molecular paths towards better control of organ rejection [news]. JAMA 1990; 263: 1184-1187.
47. Gregory C.R., Pratt R.E., Huie P., Shorthouse R. et al. Effects of treatment with cyclosporin, FK 506, rapamycin, mycophenolic acid or desoxyspergualin on vascular muscle proliferation in vitro and in vivo. Transplantant Proc 1993; 25: 770-771.
48. Gregory C.R., Smoyer W.E., Sedman A., Kershaw D.B., Valentini R.P., Johnson K., Bunchman T.E. Long-term cyclosporin therapy for pediatric nephrotic syndrome: a clinical and histological analysis. J Am Soc Nephrol 1996; 7: 543-549.
49. Hauser I.A., Renders L., Radeke H.H. еt al. Mycophenolate Mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999; 14: 58-63.
50. Hogg R., Fitzibbons L., Bruik J., Bunke M., Ault B., Baqi N., Trachtman H., Swinford R. Multicenter trial of mycophenolate mofetil (MMF) in children with steroid dependent (SD) or frequent relapsing (FR) nephrotic syndrome (NS). Report of the South West Pediatric Nephrology Study Group. Nephrol Dial Transplant 2003; 18: 261.
51. Hogg R., Fitzibbons L., Hyland K. Assessment of the accuracy and consistency of routine laboratory assay for serum creatinine concentrations compared to high perfomance liquid chromatography. Nephrol Dial Transplant 2003; 18: 642.
52. Hogg R.J., Portman R., Milliner D., Lemlley K., Eddy A., Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000; 105: 1242-1249.
53. Hong J.C., Kahan B.D. Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol 2000; 20: 108-125.
54. Hu W., Liu Z., Chen H. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus-nephritis. 2002; 115 (5): 705-709.
55. Ingulli E., Singh A., Baqi N., Ahmad H., Moazami S., Tejani A. Aggressive, long-term cyclosporin therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 1995; 5: 1820-1825.
56. Jonsson C.A., Svensson L., Carlsten H. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/mice. Clin Exp Immunol 1999; 116: 534-541.
57. Kahan B.D., Ponticelli C. Principles and Practica of Renal Transplantation. N Engl J Med 1998; 19: 1156-1162.
58. Kapitsinou P.P., Boletis J.N., Skopouli F.N., Boki K.A., Moutsopoulos H.M. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 2004; Jan 6 [epub ahead of print].
59. Koskimies O., Vilska J., Rapola J., Hallman N. Long-term outcome of primary nephrotic syndrome. Arch Dis Child 1982; 57: 544-548.
60. Kulkarni A.A., Bharat V. Shah. Mycophenolate Mofetil: A Promising Immunosuppressive Agent. JAPI 2004; 52: 33-38.
61. Lee N.J., Pawlak K., Nguyen B.T. et al. Biochemical differences among four iosinate dehydrogenase inhibitors mycophenolic acid, ribavirin, tiazofurin and selenazofurin, studied in mouse lymphomacell culture. Cancer Res 1985; 45: 5512-5520.
62. Lee W.A., Gu L., Miksztal A.R., Chu N., Leung K., Nelson P.H. Bioavailability improvement of mycophenolic acid through amino ester derivatisation. Pharm Res 1990; 7: 161.
63. Li L., Wang H., Lin S. et al. Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis; a multicentral clinical trial in China. Zhongnua Nei Kezazhi 2002; 41 (7): 476-479.
64. Li L.S., Hu W.X., Chen H.P., Liu Z.N. Comparison of mycophenolate mofetil vs cyclophosphamid pulse therapy in the induction treatment of severe diffuse proliferative lupus nephritis in Chinese population. J Am Soc Nephrol 2000: 89A.
65. MacPhee I.A.M., Spreafico S., Bewick M. et al. Pharmacokinetics of mycophenolate mofetil in patients with end stage renal failure. Kidney Int 2000; 57: 1164-1168.
66. Maes B., Claes K., Evenepoel P. et al. A prospective placebo-controlled randomized study of mycophenolate mofetil treatment for IgA nephropathy: lack of clinical efficacy after three years. Nephrology Dialysis Transplantation 2003; 18 (Suppl. 4): 343.
67. Martinelli R., Okumura A.S., Pereira L.J., Rocha H. Primary focal segmental glomerulosclerosis in children: prognostic factors. Pediatr Nephrol 2001; 16: 656-661.
68. Mendoza S.A., Tune B.M. Management of the difficult nephrotic patients. Pediatr Clin North Am 1995; 42: 1459-1468.
69. Miller G., Zimmerman R. 3rd, Radhakrishnan J., Appel G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000; 36: 250-256.
70. Mohasci P.J., Tuller D., Hulliger B., Wijngaard P.L.J. Different inhibitory effects of immunosuppressive drugs on human rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997; 16: 484-492.
71. Montane B., Abitbol C., Paredes A., Zilleruelo G., Strauss J. Mycophenolate mofetil (MMF) treatment in steroid resistant/relapsing nephrotic syndrome (NS) of childhood. J Am Soc Nephrol 1999; 10: 111A.
72. 71a. Montane B., Abitbol C., Strauss J., Zilleruelo G. Novel therapy of focal glomerulosclerosis with mycophenolate mofetil and angiotensin blockade. Pediatr Nephrol 2003; 18: 772-777.
73. Morris R.E. New small molecule immunosuppressant for transplantation: review of essential concepts. J Heart Lung Transplant 1993; 12: 275-286.
74. Morris R.E., Hoyt E.G., Murphy M.P. et al. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant I Proc 1990; 22: 1659-1662.
75. Morris R.E., Wang J. Comparison of the immunosuppressive effects of mycophenolic acid and the morpholinoethylester of mycophenolic acid (RS-61443) in recipients of heart allografts. Transplant I Proc 1991; 23: 493-496.
76. Morris R.E., Wang J., Blum J.K. et al. Immunosuppressive effects in rat and nonhuman primate recipients of heart allografts. Transplant I Proc 1991; 23 (Suppl.): 19.
77. Ng Y.Y., Huang T.P., Yang W.C. еt al. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998; 54: 864-876.
78. Nowask R., Birck R., van der Woude F.J. Mycophenolate Mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349: 774.
79. Nowask R., Gobel U., Klooker P., Hergesell O., Andrassy K., Vanderwoude F.J. Mycophenolate mofetil for systemic maintenance therapy of Wegener granulomatosis and microscopic polyangeitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10: 1965-1971.
80. O’Hair D.P., McManus R.P., Komorowski R. Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 1994; 58: 1311-1315.
81. Ophascharoensuk V., Nappakun K., Bunnachuk D. et al. Efficacy of mycophenolate mofetil and polyclonal anti-lymphocyte antibodies in severe and cyclophosphamide-resistant lupus-nephritis in Thai patients. Nephrology Dialysis Transplantation 2003; 18 (Suppl. 4): 354.
82. Penny M.J., Boyad R.A., Hall B.M. Mycophenolate Mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition. J Am Soc Nephrol 1998; 9: 2272-2282.
83. Raab M., Daxecker H., Karimi A. et al. In vitro effects of mycophenolic acid on the nucleotidi pool and on the expression of adhesion molecules of human umbilical vein endothelial cells. Clin Chem Acta 2001; 310: 89-98.
84. Romero F., Rodriguez-Iturbe B., Parra G. et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999; 55: 945-955.
85. Rothenberg M.B., Heymann W. The incidence of the nephrotic syndrome in children. Pediatrics 1957; 19: 446-452.
86. Schlesinger E.R., Sultz H.A., Mosher W.E., Feldman J.G. The nephrotic syndrome: Its incidence and implications for the community. Am J Dis Child 1968; 116: 623-632.
87. Senda M., DeLustro B., Eugui E., Natsumeda Y. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also on immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 1995; 60: 1143-1148.
88. Sintchak M., Fleming M.A., Futer O. et al. Structure and mechanisms of inosine monophosphate deshydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996; 85: 921-930.
89. Strivastava T., Simon S.D., Alon U.S. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 1999; 13: 13-18.
90. Sugomoto H., Shikata K., Wada J. et al. Advanced glycation and products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: Aminoguanidine ameliorates the overexpression of tumor-necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 1999; 42: 878-892.
91. Tarshish P., Tobin J.N., Berstein J., Edelmann C.M.J. Prognostic significance of the early course of minimal nephrotic syndrome. Report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997; 8: 769-776.
92. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
93. Tune B.M., Lieberman E., Mendoza S.M. Steroid-resistant nephrotic focal segmental glomerulosclerosis: a treatable disease. Pediatr Nephrol 1996; 10: 772-778.
94. Ulinski T., Ranchin B., Said M.-H. et al. Switch from cyclosporine A (CyA) to mycophenolate mofetil improves kidney function in children with nephritic syndrome and CyA-induced nephrotoxicity. Nephrology Dialysis Transplantation 2003; 18 (Suppl. 4): 261.
95. Vanrenterghem Y. The use of mycophenolate mofetil (Cellcept) in renal transplantation. Nephron 1997; 76: 393-399.
96. Yoing C.J., Sollinger H.W. RS-61443: a new immunosuppressive agent. Transplant Proc 1994; 26: 3144-3146.
97. Zhao M., Chen X., Chen Y. et al. Mycophenolate mofetil in the treatment of primary nephrotic syndrome. ZhonguhuaYi Xue Za Zhi 2001; 81 (9): 528-531.
98. Zhao M., Chen X., Chen Y., Liu Z., Liu Y., Lu Y., Zhang Y., Wang H. Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome. Nephrology 2003; 8; 3: 105-109.
99. Ziswiler R., Steinmann-Niggli K., Kappeler A., Daniel C., Marti H.P. Mycophenolic acid: a new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1998; 9: 2055-2066.

Другие статьи по теме

• Результаты эпидемиологического исследования нефротического синдрома у детей по данным регионального регистра больных
• Значение генетики и протеомики в понимании механизмов развития и прогрессирования нефротического синдрома у детей
• Первый опыт использования мофетила микофенолата в лечении гломерулонефрита у детей
• Мофетила микофенолат в терапии нефротического синдрома у детей